Hexal Australia

Hexal Australia is a subsidiary of the global pharmaceutical company Sandoz, which is itself a division of the Swiss multinational Novartis. Hexal Australia specializes in the development, production, and marketing of high-quality, affordable medicines, particularly generic drugs.

History

Hexal Australia was established as a part of Hexal AG, a German pharmaceutical company founded by pharmacists Thomas Strüngmann and Andreas Strüngmann in 1986. Hexal AG was acquired by Sandoz in 2005, making Hexal Australia a part of the Sandoz global network.

Products and Services

Hexal Australia offers a wide range of generic medicines across various therapeutic areas, including cardiovascular diseases, diabetes, respiratory diseases, oncology, and pain management. The company is committed to improving access to high-quality medicines and contributing to the sustainability of the Australian healthcare system.

Research and Development

Hexal Australia, in line with Sandoz's global strategy, invests significantly in research and development (R&D). The company's R&D activities focus on the development of complex generics, biosimilars, and novel therapeutic products.

Corporate Responsibility

Hexal Australia is committed to operating in a socially and environmentally responsible manner. The company's corporate responsibility initiatives align with the broader sustainability goals of Novartis, which include improving global health, operating responsibly, and contributing to society.

See Also

• Sandoz
• Novartis
• Generic drug
• Biosimilar

References

‎

‎